Instant Report
FDF

Date: 10-Mar-2021

Abbott Introduces NeuroSphere Virtual Clinic First Of Its Kind Remote Neuromodulation Patient Care Technology In The US

Abbott (NYSE: ABT) announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering from chronic pain or movement disorders who don't live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19.

Abbott's NeuroSphere Virtual Clinic gives patients the flexibility and comfort of receiving care anywhere* by connecting with their doctor via secure in-app video chat and an integrated remote programming feature, now available within the proprietary Abbott patient controller app. NeuroSphere Virtual Clinic enables clinicians to prescribe new treatment settings remotely to the patient's neurostimulation device using the clinician programmer app and a new, simple and secure remote care connection. This advancement gives patients confidence in their care and the convenience to manage their therapy in a way that fits their lifestyle.